The influence of host response on colorectal cancer prognosis

Clinical Colorectal Cancer

Volumn 4, Issue 1, 2004, Pages 38-45

  Shunyakov, Leo ^a   Ryan, Charlotte K ^a   Sahasrabudhe, Deepak M ^a   Khorana, Alok A ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b NONE   (United States)

Author keywords

Intraepithelial lymphocytes; Microsatellite instability; Tumor associated macrophages; Tumor infiltrating lymphocytes

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIGEN PRESENTING CELL; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; DENDRITIC CELL; EOSINOPHIL; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MAST CELL; MICROSATELLITE INSTABILITY; NATURAL KILLER CELL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 3042616111     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.008     Document Type: Review

References (65)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
4. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-1206.
5. Boulay JL, Mild G, Lowy A, et al. SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J Cancer 2002; 87:630-634.
6. Elsaleh H, Powell B, McCaul K, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001; 7:1343-1349.
7. Longley DB, McDermott U, Johnston PG. Predictive markers for colorectal cancer: current status and future prospects. Clin Colorectal Cancer 2003; 2:223-230.
8. Greco F, Figlin R, York M, et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996; 14:2674-2681.
9. Holcombe RF, Jacobson J, Dakhil SR, et al. Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009. Cancer Immunol Immunother 1999; 48:533-539.
10. Nicolini A, Mancini PA, Ferrari P, et al. Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients. Biomed Pharmacother 1996; 50:344-349.
11. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80:30-36.
12. Hawkins MJ, Atkins MB, Dutcher JP, et al. A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunother 1994; 15:74-78.
13. Khorana AA, Ryan CK, Cox C, et al. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003; 97:960-968.
14. Dalerba P, Maccalli C, Casati C, et al. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003; 46:33-57.
15. Albanopoulos K, Armakolas A, Konstadoulakis, MM. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am J Gastroenterol 2000; 95:1056-1061.
16. Barbera-Guillem E, Nyhus JK, Wolford CC, et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002; 62:7042-7049.
17. Dvorak H. Tumors: wounds that do not heal. N Engl J Med 1986; 315:1650-1659.
18. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-555.
19. Sica A, Saccani A, Mantovani A. Tumor-associated macrophages: a molecular perspective. Int Immunopharmacol 2002; 2:1045-1054.
20. Chu CS, Woo EY, Toll AJ, et al. Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. Clin Immunol 2002; 102:291-301.
21. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
22. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13:265-270.
23. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254-265.
24. Ohtani H, Naito Y, Saito K, et al. Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity? Lab Invest 1997; 77:231-241.
25. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64:275-290.
26. Toomey D, Harmey J, Condron C, et al. Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 1999; 28:29-41.
27. Sugita J, Ohtani H, Mizoi T, et al. Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions. Jpn J Cancer Res 2002; 93:320-328.
28. Oberg A, Samii S, Stenling R, et al. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis 2002; 17:25-29.
29. Funada Y, Noguchi T, Kikuchi R, et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003; 10:309-313.
30. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172:1535-1545.
31. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87:3336-3343.
32. Luttun A, Tjwa M, Carmeliet P, et al. Placental growth factor (PIGF) and its receptor Fit-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann NY Acad Sci 2002; 979:80-93.
33. Schwaab T, Weiss JE, Schned AR, et al. Dendritic cell infiltration in colon cancer. J Immunother 2001; 24:130-137.
34. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989; 63:496-503.
35. Suzuki A, Masuda A, Nagata H, et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol 2002; 196:37-43.
36. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001; 98:8809-8814.
37. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25:97-138.
38. Mulder WM, Stern PL, Stukart MJ, et al. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res 1997; 3:1923-1930.
39. Svennevig JL, Lunde OC, Holter J, et al. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984; 49:375-377.
40. Jass J. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986; 39:585-589.
41. Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998; 42:673-679.
42. Compton C, Fenoglio-Preiser CM, Fielding LP, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88:1739-1757.
43. Menon AG, Fleuren GJ, Alphenaar EA, et al. A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer. Cancer Immunol Immunother 2003; 52:121-126.
44. Nanni O, Volpi A, Frassineti GL, et al. Role of biological markers in the clinical outcome of colon cancer. British J Cancer 2002; 87:868-875.
45. Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189:487-495.
46. Roncucci L, Fante R, Losi L, et al. Survival for colon and rectal cancer in a population-based cancer registry. Eur J Cancer 1996; 32:295-302.
47. Ropponen KM, Eskelinen MJ, Lipponen PK, et al. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997; 182:318-324.
48. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-3494.
49. Guidoboni M, Gafa R, Viel A, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001; 159:297-304.
50. Cianchi F, Messerini L, Cortesini C, et al. Character of the invasive margin in colorectal cancer: does it improve prognostic information of Dukes staging? Dis Colon Rectum 1997; 40:1170-1175.
51. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-213.
52. Saeterdal I, Bjorheim J, Gjertsen MK, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001; 98:13255-13260.
53. Bustin SA, Li SR, Phillips S, et al. Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite-instability-positive tumours. Tumour Biol 2001; 22:294-298.
54. Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001; 91:2417-2422.
55. Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154:1805-1813.
56. Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001; 48:360-366.
57. Kapiteijn E, Liefers GJ, Los LC, et al. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001; 195:171-178.
58. Coca S, Perez-Piqueras J, Martinez D, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79:2320-2328.
59. Jonges LE, Nagelkerke JF, Ensink NG, et al. Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest 2001; 81:681-688.
60. Fernández-Aceñero MJ, Galindo-Gallego M, Sanz J, et al. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000; 88:1544-1548.
61. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study. BMC Cancer 2001; 1:7.
62. Sabattini E, Bisgaard K, Ascani S, et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 1998; 51:506-511.
63. Werner M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000; 24:1016-1019.
64. Helander KG. Kinetic studies of formaldehyde binding in tissue. Biotech Histochem 1994; 69:177-179.
65. Johnson CW. Issues in immunohistochemistry. Toxicol Pathol 1999; 27:246-248.